{
    "root": "55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe",
    "value": "20250301",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        }
    ],
    "indications": "Ezetimibe tablets are indicated:\n                  \n                  \n                     \n                        •\n                        \n                           In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). \n                        \n                     \n                     \n                        •\n                        In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. \n                     \n                     \n                        •\n                        In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. \n                     \n                     \n                        •\n                        In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). \n                     \n                     \n                        •\n                        As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. \n                     \n                  \n                  \n                     When ezetimibe tablet is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.",
    "contraindications": "•The recommended dose of ezetimibe tablet is 10 mg orally once daily, administered with or without food. \n                     \n                        •\n                        If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. \n                     \n                     \n                        •\n                        Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets. \n                     \n                     \n                        •\n                        Administer ezetimibe tablets at least 2 hours before or 4 hours after administration of a bile acid sequestrant [seeDrug Interactions (\n                        \n                        \n                           7\n                           )].",
    "warningsAndPrecautions": "Ezetimibe Tablets, USP 10 mg, are white to off-white, capsule-shaped, flat, beveled edged tablets engraved with ‘G80’ on one side and plain on the other side. They are supplied as follows: \n                  Bottles of 30, NDC 82804-211-30 \n                  Store Ezetimibe Tablets, USP at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions": "Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see Adverse Reactions (6.2)].\n                     \n                         \n                        When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (\n                        \n                        \n                           5.1\n                           )]."
}